Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET

Company Participants

Kate Rausch - Vice President, Investor Relations & Corporate Affairs
Paul Bolno - President & Chief Executive Officer
Anne-Marie Li-Kwai-Cheung - Chief Development Officer
Kyle Moran - Chief Financial Officer

Conference Call Participants

Steven Seedhouse - Raymond James
Joon Lee - Truist
Salim Syed - Mizuho
Luca Issi - RBC
Catherine Novack - Jones Trading
Madison El-Saadi - B. Riley

Operator

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded and webcast. I'll now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Kate Rausch

Thank you, operator. Good morning, and thank you for joining us to discuss our recent business progress and review Wave's Q3 2024 financial results. Joining me today with prepared remarks are Dr. Paul Bolno, President and Chief Executive Officer Anne-Marie Li-Kwai-Cheung, Chief Development Officer and Kyle Moran, Chief Financial Officer. The press release issued this morning is available on the Investors section of our website, www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason.

I'd now like to turn the call over to Paul.

Paul Bolno

Thanks, Kate. Good morning and thank you all for joining us on today's call. It's an exciting time for Wave. This year we have executed ahead of plan, delivered three positive clinical data sets, received supportive initial feedback from FDA on HD, rapidly advanced our obesity program towards the clinic, and strengthened our balance sheet to support our maturing and growing pipeline.

Our best-in-class RNA platform is consistently translating in the clinic and demonstrating how we can uniquely design, and advance first and best-in-class RNA medicine that's reimagining what's possible for patients. Our achievements have set us up for another potentially transformative year in 2025 as we aim to build on our strong momentum and deliver on key milestones from four clinical programs.